SciELO - Scientific Electronic Library Online

 
vol.25 issue2Patterns of treatment for childhood malaria among caregivers and health care providers in Turbo, ColombiaPorcine plasmin: determination of kinetic parameters and comparison with human plasmin author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Iatreia

Print version ISSN 0121-0793

Abstract

PENA SIADO, Jorge Enrique; VELEZ VILLEGAS, María Clara; SANCHEZ HERNANDEZ, Diana Paola  and  DONADO GOMEZ, Jorge Hernando. Benefits of hidroxyurea therapy in children with sickle cell disease. Iatreia [online]. 2012, vol.25, n.2, pp.105-110. ISSN 0121-0793.

Objective: To assess the toxicity and benefits of hydroxyurea (HU) in the management of children with sickle cell disease (SCD). Materials and methods: a descriptive observationalretrospective study of patients with SCD treated with HU was carried out at Hospital Pablo Tobón Uribe in Medellin, Colombia, from May 2004 to September 2009. Sixteen patients aged under 15 years were treated with this drug; out of them, 11 (68.8%) were male. All patients had sickle cell anemia (Hb SS). The variables were studied before and after initiation of HU. Results: Average number of painful crises was 3.31 before and 1.13 after HU (p = 0.006); average number of red blood cell transfusions was 2.69 before and 0.75 after HU (p = 0.112); average number of acute chest syndrome episodes was 0.19 before and 0.13 after HU (p = 0.705); average number of hospitalizations was 1.94 before and 1.06 after HU (p = 0.155). One patient (6.3%) had hematologic toxicity, two patients (12.5%) had liver toxicity, and three patients (18.6%) had strokes. Renal toxicity was not found. There were no malignancies. Conclusion: HU significantly reduced the frequency of painful crises in our patients with SCD. Toxicity was generally acceptable. Prospective multicenter, double-blind, placebo-controlled studies are required in order to define the role of HU in pediatric patients with SCD.

Keywords : Hospitalization; Hydroxyurea; Sickle Cell Anemia; Toxicity; Transfusion.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License